POTASSIUM CHLORIDE | N019439 | MERCK INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lachman Consultant Services, Inc. FDA-2018-P-0870 · 7 docket documents Lachman Consultant Services, Inc. filed this citizen petition pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA declare Potassium Chloride Extended Release Tablets, 8 mEq, suitable for submission as an abbreviated new drug application (ANDA), with th | Other | 2018-02-26 | Denied | Lachman Consultant Services, Inc. |
Citizen Petition from King & Spalding LLP FDA-2006-P-0011 · 8 docket documents King & Spalding LLP filed this citizen petition requesting that the FDA declare an abbreviated new drug application may be submitted for potassium chloride oral solution products in 10% and 5% strengths, using K-DURS Extended Release Tablets as the reference listed drug under NDA 019439. The petitio | Other | 2008-08-13 | Withdrawn | King & Spalding LLP |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.